Not All Types of Atrial Fibrillation Carry the Same Stroke Risk, but Most Benefit From Oral Anticoagulation
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Atrial fibrillation (AF) is the most commonly encountered arrhythmia worldwide, with an estimated prevalence of ≈3% in adults ≥20 years of age1 and with an even greater prevalence in subjects with conditions such as hypertension, valvular heart disease, or chronic kidney disease. AF is classified according to its pattern of occurrence, and recent guidelines have proposed a consensus definition of the temporal occurrence of AF. Paroxysmal AF is self-terminating and lasts no longer than 7 days; AF episodes lasting longer than 7 days or necessitating termination by cardioversion are defined as persistent AF; and permanent AF is defined as AF without intercurring sinus rhythm, which is accepted by the patient and the physician.1
See Article by Link et al
An often debated issue is whether the type and the duration of AF affect stroke risk. Early findings from the SPAF trials (Stroke Prevention in Atrial Fibrillation)2 and an analysis of the ACTIVE W study (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events)3 suggested a similar stroke risk in all types of AF. However, these studies were limited by methodological issues such as moderate sample sizes with relatively low event rates. More recently, subanalyses from the large …